Resiquimod and other immune response modifiers as vaccine adjuvants (Q34700325)

4 August 2017

1 reference

title

Resiquimod and other immune response modifiers as vaccine adjuvants (English)

1 reference

4 August 2017

1 reference

John P Vasilakos

6

0 references

Kenneth E. Lipson

object named as

Kenneth E Lipson

3

0 references

author name string

Mark A Tomai

1

1 reference

4 August 2017

Richard L Miller

2

1 reference

4 August 2017

William C Kieper

4

1 reference

4 August 2017

Isidro E Zarraga

5

1 reference

4 August 2017

1 October 2007

1 reference

Expert Review of Vaccines

4 August 2017

1 reference

4 August 2017

6

1 reference

4 August 2017

835-847

1 reference

4 August 2017

5

1 reference

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

4 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Toll-like receptors and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Toll-like receptors in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Recognition of pathogen-associated molecular patterns by TLR family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Activation of anti-hepatitis C virus responses via Toll-like receptor 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Type I interferon dependence of plasmacytoid dendritic cell activation and migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Requirement of 8-mercaptoguanosine as a costimulus for IL-4-dependent mu to gamma1 class switch recombination in CD38-activated B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Immunomodulating and antiviral activities of the imidazoquinoline S-28463.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

IRF-7 is the master regulator of type-I interferon-dependent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Imiquimod 5% cream (Aldara).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Medical therapies for non-melanoma skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Successful combination of local CpG-ODN and radiotherapy in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

In situ photoimmunotherapy: a tumour-directed treatment for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

Cellular Requirements for Cytokine Production in Response to the Immunomodulators Imiquimod and S-27609

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.835

21 January 2018

Identifiers

DOI

10.1586/14760584.6.5.835

1 reference

release_fcto42vgvrhk5gmzy4q4nvpvmu

4 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fcto42vgvrhk5gmzy4q4nvpvmu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference